-
Article
Publisher Correction: A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells
-
Article
A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells
Effective antitumour immunity depends on the orchestration of potent T cell responses against malignancies1. Regression of human cancers has been induced by immune checkpoint inhibitors, T cell engagers or chimer...
-
Article
Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation
Despite the significant therapeutic advances provided by immune-checkpoint blockade and chimeric antigen receptor T cell treatments, many malignancies remain unresponsive to immunotherapy. Bispecific antibodie...
-
Article
Open AccessNatural killer cells limit the clearance of senescent lung adenocarcinoma cells
Senescence is an important p53-controlled tumor suppressor program that not only opposes the proliferation of cancer cells but also promotes their immune-mediated clearance in certain contexts. In hepatocellul...
-
Article
Open AccessDissecting the tumor micro-environment in triple negative breast cancer identifies a mutually exclusive expression pattern of the immune co-inhibitory molecules B7-H4 and PD-L1
-
Article
Therapeutic siRNA silencing in inflammatory monocytes in mice
In vivo silencing in specific cell types remains the main obstacle for therapeutic applications of siRNAs. Leuschner et al. now show that an optimized lipid nanoparticle delivers siRNA to inflammatory monocytes i...
-
Chapter and Conference Paper
Camel Single-Domain Antibodies as Modular Building Blocks to Make Bivalent Constructs for Use in Immunotherapy of Cancer
Over the last years there has been a growing interest in the use of antibodies and antibody fragments as therapeutic entities to treat cancer. Identification of the smallest antibody fragment still capable of ...